The latest price target for WAVE Life Sciences (NASDAQ:WVE) was reported by Mizuho on November 21, 2024. The analyst firm set a price target for $22.00 expecting WVE to rise to within 12 months (a possible 62.96% upside). 26 analyst firms have reported ratings in the last year.

The latest analyst rating for WAVE Life Sciences (NASDAQ:WVE) was provided by Mizuho, and WAVE Life Sciences maintained their outperform rating.

The last upgrade for WAVE Life Sciences Ltd happened on October 16, 2024 when Raymond James raised their price target to $22. Raymond James previously had an outperform for WAVE Life Sciences Ltd.

There is no last downgrade for WAVE Life Sciences.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of WAVE Life Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for WAVE Life Sciences was filed on November 21, 2024 so you should expect the next rating to be made available sometime around November 21, 2025.

While ratings are subjective and will change, the latest WAVE Life Sciences (WVE) rating was a maintained with a price target of $19.00 to $22.00. The current price WAVE Life Sciences (WVE) is trading at is $13.50, which is out of the analyst’s predicted range.